SMO and medulloblastoma: Indeed, the SMO inhibitors Vismodegib and Sonidegib are FDA-approved to treat SMO hyperactivity in BCC and have shown promising efficacy in SHH-dependent preclinical models of medulloblastoma and others [222,223,224,225,226,227,228,229,230,231].